This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Russell D. Rollinson, FRACP; Bernard S. Gilligan, FRACP

Arch Neurol. 1979;36(1):44-45.

Abstract
• A patient with postanoxic action myoclonus (Lance-Adams syndrome) was severely disabled with this movement disorder. Valproate sodium was administered orally, with complete resolution of the myoclonus. This favorable response has been maintained for two years. Excessive yawning, the only side effect encountered, was dose related and was abolished with the addition of pimozide to the drug regimen.

Author Affiliations
From the Department of Neurology, Bowman Gray School of Medicine, Winston-Salem, NC (Dr Rollinson), and the Alfred Hospital, Melbourne (Dr Gilligan). Dr Rollinson is now with the Department of Neurology, Vanderbilt University, Nashville, Tenn.

Footnotes
Accepted for publication Nov 21, 1977.

Reprint requests to Department of Neurology, Vanderbilt Medical Center, Vanderbilt University, Nashville, TN 37232 (Dr Rollinson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Childhood Myoclonus With Botulinum Toxin Type A
Awaad et al.
J Child Neurol 1999;14:781-786.
ABSTRACT  

Topical Review: Antidyskinetic Drug Therapy for Pediatric Movement Disorders
Pranzatelli
J Child Neurol 1996;11:355-369.
ABSTRACT  

Segmental Myoclonus: Clinical and Pharmacologic Study
Jankovic and Pardo
Arch Neurol 1986;43:1025-1031.
ABSTRACT